Allogene Therapeutics (ALLO) Prices 11.7M Share Common Offering at $47/Sh

Allogene Therapeutics, Inc. (NASDAQ: ALLO), today announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price to the public of $47.00 per share. The gross proceeds from this offering are expected to be approximately $550.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene. The offering is expected to close on or about June 4, 2020, subject to customary closing conditions. In addition, Allogene has granted the underwriters a 30-day option to purchase up to 1,755,319 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Goldman Sachs & Co. LLC, Jefferies LLC and Cowen and Company, LLC are acting as joint lead book-running managers for the offering. Piper Sandler & Co. is also acting as book-running manager. Canaccord Genuity LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. are acting as co-lead managers.

You May Also Be Interested In

• William Blair Starts Surrozen Inc. (SRZN) at Outperform
• Andersen closes secondary offering of 4.9M shares at $44 each
• Oruka Therapeutics (ORKA) files $1B mixed shelf